Exicure (XCUR) Stock Price, News & Analysis

Company Overview

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $10.22 to $11.31
• 50-Day Range: $7.90 to $31.99
• 52-Week Range: $1.44 to $36.00
• Volume: 16,348 shs
• Average Volume: 141,403 shs
• Market Capitalization: $28.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Exicure Stock Analysis - MarketRank™

Exicure scored higher than 36% of companies evaluated by MarketBeat, and ranked 837th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Exicure.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Exicure is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exicure is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Exicure has a P/B Ratio of 6.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.54% of the float of Exicure has been sold short.

Short Interest Ratio / Days to Cover

Exicure has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exicure has recently decreased by 46.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exicure does not currently pay a dividend.

Dividend Growth

Exicure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.67

Percentage of Shares Shorted

11.54% of the float of Exicure has been sold short.

Short Interest Ratio / Days to Cover

Exicure has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exicure has recently decreased by 46.25%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.19

News Sentiment

Exicure has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Exicure this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exicure insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.90% of the stock of Exicure is held by insiders.

Percentage Held by Institutions

42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XCUR Stock Analysis - Frequently Asked Questions

How have XCUR shares performed this year?

Exicure's stock was trading at $13.67 at the beginning of 2025. Since then, XCUR shares have decreased by 20.9% and is now trading at $10.81.
View the best growth stocks for 2025 here.

How were Exicure's earnings last quarter?

Exicure, Inc. (NASDAQ:XCUR) issued its quarterly earnings results on Friday, November, 19th. The company reported ($40.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($13.50) by $27.00. The company had revenue of ($3.68) million for the quarter, compared to analyst estimates of $0.80 million.

When did Exicure's stock split?

Shares of Exicure reverse split before market open on Tuesday, August 27th 2024. The 1-5 reverse split was announced on Monday, August 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Exicure?

Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Exicure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exicure investors own include Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Tesla (TSLA), Meta Platforms (META), NIO (NIO), Viking Therapeutics (VKTX) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 11/19/2021
• Today: 1/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XCUR
• CUSIP: N/A
• CIK: 1698530
• Web: www.exicuretx.com
• Phone: (847) 673-1700
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,910,000.00
• Net Margins: N/A
• Pretax Margin: -799.80%
• Return on Equity: -190.90%
• Return on Assets: -36.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.71
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $28.83 million
• Price / Sales: 0.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.75 per share
• Price / Book: 6.16

Miscellaneous

• Outstanding Shares: 2,610,000
• Free Float: 2,504,000
• Market Cap: $28.15 million
• Optionable: Not Optionable
• Beta: 3.81